(1 year ago)
Lords ChamberThe noble Baroness says much more eloquently what I was trying to say earlier. If you deal with various other health outcomes, you have a much better chance of getting a sustained improvement, for children in particular. I absolutely agree with what she says and I am very happy to work with Gavi on this.
My Lords, following on from the previous question, can the Minister tell the House how the Government do the metrics to ensure that the impacts of the nutrition programmes are as effective as they could be, particularly, for example, in areas of health? Can he give us some indication of how that is done? I have not read the White Paper, admittedly.
The White Paper seeks to set out how we hold ourselves accountable to the amounts of ODA that we give and to which areas. I cannot, particularly in a short moment here—even if I knew it—give the noble Lord the details of the metrics, but I urge him to look at the White Paper and, if he still requires information, I would be very happy to arrange for him to meet officials or to write to him.
(1 year, 5 months ago)
Lords ChamberImports into the UK must comply with our existing import requirements. Products produced to different environmental and animal welfare standards can be placed on the UK market if they comply with these requirements. We are taking a tailored approach in each of our new free trade agreements. For example, pork, poultry and eggs were excluded from our agreement with Australia, and in our agreements with Australia and New Zealand, we secured non-regression and non-derogation clauses on animal welfare. This will be a feature of future agreements.
My Lords, I take this opportunity to thank the noble Lord for his courteous correspondence after the conclusion of the Genetic Technology (Precision Breeding) Act. Apropos of that Act, it is very clear that, when we start to modify animals, there will be a number of mutations which are likely to be unpredictable. Can the Minister give us some idea of how we will control the potential for animal cruelty when mutant animals are produced in this sort of way?
I am grateful to the noble Lord for his involvement with that Act. He challenged me and the House to become more knowledgeable during our debates on it. We think that the Act will have huge benefits for animal welfare; I have two examples for the noble Lord. The Roslin Institute and Genus have developed gene-edited versions of pigs, which could improve the situation with regard to porcine reproductive and respiratory syndrome, a terrible disease of that animal. The other example is pancreatic necrosis virus in salmon. We want to make sure that we are regulating this properly; we talked about that throughout debates on the Act. We now have a system in which there is transparency about how we regulate that, but I will continue to keep the House informed as we develop that.
(1 year, 10 months ago)
Lords ChamberMy Lords, I thank the noble Baroness, Lady Bennett, for her Amendment 12, which would require details of the specific gene editing event and the whole-genome sequence of a qualifying precision-bred organism to be made publicly available for its release into the environment. The noble Baroness’s Amendment 13 to Clause 3 would require that regulations made under this clause to establish a public register containing this information are subject to the affirmative procedure.
It is not our intention to require breeders to include sequence data as part of their release or marketing notices. I have discussed this previously following an amendment tabled by the noble Lord, Lord Winston, in Committee. We have since had a very useful meeting with the noble Lord and our scientific advisors, ACRE, to explore why whole- genome sequencing information has limited value in most cases, and the noble Lord has not retabled his amendment on Report.
This type of information has limited value because there is a significant degree of genetic variation between individual plants and animals within a species, which is more or less the point that the noble Lord, Lord Krebs, was making. This amount of background noise means that the value in requiring whole-genome sequences is limited in terms of addressing regulatory questions; for example, questions about the precision-bred status of a plant or animal. Additionally, the release notice that researchers are required to submit to Defra will be in line with the requirements of the Genetically Modified Organisms (Deliberate Release) (Amendment) (England) Regulations 2022, which were agreed by the affirmative procedure.
Our intention is that information provided in release notices will be published on the precision breeding register and will include the relevant and necessary information about the precision-bred organism in it. We also intend to require developers to confirm that the organisms that they intend to release in research trials meet the criteria in the Bill. The technical details of this notice will be prescribed by regulations, prepared with input from the advisory committee appointed to advise the Secretary of State on the regulatory status of these organisms and, in accordance with the amendments to Clause 4 that I have tabled, our intention is that such regulations will be scrutinised using the affirmative procedure before they are made.
I hope that this reassures noble Lords and that the noble Baroness, Lady Bennett, is persuaded to withdraw this amendment and not move her additional amendment to Clause 3, which would specify the parliamentary procedure for the delegated power that her substantive amendment would insert.
I always pay particular attention to points raised on secondary legislation by the noble Baroness, Lady Bakewell. As a member of the Secondary Legislation Scrutiny Committee, she is very good at holding me to account on these. I did not quite understand her point about Clause 3 because there are no regulations in Clause 3 and therefore no requirement for it to be affirmative or negative.
We remain of the belief that the matters to be set out in the regulations under the powers in Clauses 4(3) and 6(2) are administrative in nature. However, the Government acknowledge that these provisions are of significant public interest. We have heard this previously in the House and the Delegated Powers and Regulatory Reform Committee has raised this as well. We have considered these matters closely and have decided to change the procedure from negative to affirmative for both powers. These changes will increase the scrutiny when these powers are used to prescribe the information which must be provided to the Secretary of State by a person who wishes to release or market a precision-bred organism. I hope that noble Lords feel that I was serious in Committee when I said that I had listened to them. I hope that they feel that this improves the Bill. Regulations under Clause 4(1)(b) would be administrative in nature, not of significant public interest, and will remain subject to the negative procedure. I hope that this reassures noble Lords.
Amendments 24 and 25 will increase the level of scrutiny when powers are used to prescribe information that must be included in the precision breeding register. The Government acknowledge that these provisions are of significant public interest. We accept noble Lords’ concerns about the level of scrutiny for such provisions. Therefore, we will change the parliamentary procedure from negative to affirmative for the power in Clause 18(1). Regulations under Clause 18(6) regarding the keeping of the register, which is an administrative matter and, again, not of significant public interest, will remain under the negative procedure.
My Lords, I thank the Minister for what he has just said, but can he answer this question about whole-genome sequencing?
When we first started genome sequencing, it was laborious, expensive, time-consuming, and so on. It is now a pretty rapid process and can be done without huge expense. Does the Minister not agree that one of the reasons for doing this is not just marketing—because of course there are different issues there, which is how we are addressing this—but the advantage of getting more knowledge about what we are doing? The advantage there would be seeing where things are moving within the organisms that we are trying to edit. That is important as a research tool because, ultimately, we are doing something that—admittedly—we do not fully understand, and this would greatly increase knowledge. Does he feel that this is a relevant point?
It is entirely a relevant point, and was much on our minds when we debated some months ago a research measure in secondary legislation to allow the development of plant precision editing but not for it to be taken forward to market. The noble Lord is absolutely right that this is fast-moving and that we therefore need to be clear about how we regulate: that we are regulating a research process and a process to take products to market. Ministers will have to be clear about the intention of the organisation taking that forward. I hope, through the changes that we made, that there will be greater parliamentary scrutiny, that people with real knowledge, particularly in this place, will be able to scrutinise that, and that the Secretary of State of the day will have the best available information about what is being taken forward and why—whether it is just for research. The point made by the noble Lord about the value of research of products that will never go to market, that it is just to understand a particular aspect of genomic sequencing, is crucial.
(2 years ago)
Lords ChamberThe amount of time we spent in the department working with real experts in this field to get the terminology right means that I hope we can persuade other countries to adopt our definitions. I know that I am not going to find total agreement on this legislation with the noble Baroness, but I can try. As I explained at some length—and I apologise to noble Lords, but I think this is a really important part of this Bill—we have arrived at this definition in a coherent way. Of course, we are constantly looking at how other countries are doing this. We do not want to be left behind, but we want to keep this safe; we want to see what is happening in the EU, but we want to make sure we are giving our scientists and our businesses the right guidelines around which to develop a really exciting new area of technology.
I am very grateful to the Minister for his consideration of what I think are difficult areas in this Bill, which I think remain—we have not solved the problem yet. One of the things I really loathe in Committee is people who move an amendment then take a very long time making a long speech, which bores everybody because they have already heard it, but I feel I have to address a few points specifically. I will not do it again later in this Bill. I think I have views on every single amendment, but I will be careful not to mention them.
The noble Baroness, Lady McIntosh of Pickering, mentioned Dolly the sheep. I think Dolly the sheep is a particularly interesting issue, because one thing which will not have escaped your Lordships’ attention is that Dolly the sheep had exactly the same DNA as wherever else she was cloned. Yet animals with the same DNA do not always express the same genes. For example, identical twins in humans are often quite different in many subtle ways, including their fingertips, brain functions, thought processes and so on.
We have to accept that there are many characteristics which are not necessarily demanded, essentially, by the DNA itself but by other things as well. In particular, one of the things we have not yet discussed is the problem of epigenetics; it does come into the Bill. We know that genes can express in different ways under different environmental conditions. That expression can be altered from the very beginning of conception—that is what we are talking about here—which could be, for example, in vitro fertilisation. Of course, that is mentioned in the Bill.
One of the concerns I have about IVF, having been involved with it since its very beginning, is that we still have no long-term follow up on what it means in terms of epigenetics—that is, how genes will express in the future. There are many examples where the progeny of a species—for example, a mouse—may show complete changes with regard to obesity, for instance, due to an insult four generations earlier. One has to accept that these changes occur very early; the mothers are fed with fats at the very earliest stages of pregnancy, and four generations later, we see a sex-determined link with obesity in the progeny. These sorts of issues are not teased out here.
Clearly, a great deal of doubt is encompassed in the Bill and in the science of it. As the noble Lord rightly said, we must all have a degree of humility in trying to work out what is best. He and I, and I think most people in this Chamber, would agree that we are mostly concerned about one thing: the environment. We are concerned about climate change and how we might adversely affect our environment. As we will come to later with the release of organisms, one thing that is very clear is that sometimes in the past—with natural causes—organisms have been released into the environment. We can think of the hornet in Britain, the Bufo toad in Australia, or the fungus which causes elm disease in England. Those things have all been produced by simply being involved in our environment, with colossal difficulties. Of course, we do not ultimately know whether this is a problem with modified organisms.
There is one thing which is not discussed here but which we need to consider. What we have forgotten, partly, is evolution. We are trying to evolve a species in one step, and that is a difficulty. If you take the human species, since Homo sapiens was first in east Africa 100,000 years ago, there have probably been about 5,000 families of humans—that is all. We have not evolved very much; the human brain remains very much the same. It takes a very long time for it to change even small amounts. What we are doing here is expecting rapid change for the benefit of ourselves and, we hope, of the planet too, but the problem is that we are dealing with an environment that is constantly balanced and balancing. We are at risk of damaging that balance with so many things that we do, and I regret to say that this is one of the reasons we have to be very careful when we come at the end of the discussion to the problem of balance and, therefore, how we release these organisms into the environment and control that. That is why the Bill is so important.
Without any further ado—I have already spoken for too long—I simply ask permission to withdraw my amendment.
As I said, I can see this finding a use in forestry and in some ornamental crops. I think the early work will be done in areas that I outlined, including drought resistance and reducing the requirement for input such as fertilisers and sprays, but we want to include the ornamental sector in time. There are 30 million gardeners in this country, and we want to unlock their potential to be part of a great green revolution, but I do not think that that will be the priority here. The priority will be food.
Then why not restrict the Bill to agriculture and horticulture? There are, of course, mechanical engineering reasons for wanting some plants or indeed animals for non-food purposes.
With respect, I would not want to do that. In the same way that we are insisting that these measures can be achieved over a longer period of time through traditional plant-breeding techniques, if they are safe, it can be applied for food crops and in protection of our trees and woodlands, and it may have applications in other areas which will help our economy, particularly our green economy. I would not want to restrict it from those sectors.
My Lords, when I was in another place, there was a free vote on the smoking ban. I remember a panicked Back-Bencher coming towards the Lobbies and saying that he did not know how to vote, because he hated smoking but loved freedom—what was he to do? Someone just said to him, “That way for freedom from smoke; that way for freedom to smoke.” I mention that because it shows that you can look down two ends of a telescope and come at this from two directions. I entirely understand that people who want to oppose the Bill in its entirety will find hooks on which to hang that belief, and that others who see merit in this will try to see a path down which to go.
I will try to address the points raised. First, for clarity, I say to the noble Baroness, Lady Bennett, that fungi are out of the scope of the Bill. I am sure she will be pleased to hear that. I say to the noble Baroness, Lady Jones, that animals were not a late inclusion into the Bill. There was a consultation in March 2021 which included animals, and a response to that was published in September 2021, so I do not think the idea that this was a late entry into the Bill stacks up.
I am grateful for the opportunity to further build on the Government’s position on why we think it is vital that animals remain part of the Bill. There are many potential benefits of enabling precision breeding in animals, including, as we have heard, to improve the health, welfare and resilience of animals. We have a real opportunity to harness the great research that is already taking place in the UK. Noble Lords highlighted some of this great potential during Second Reading, but to reiterate, our leading scientists are already using precision breeding to develop resistance to a range of diseases that impact animals across the country.
We have already mentioned at Second Reading research focused on resistance to bird flu in chickens, resistance to sea lice in farmed salmon and resistance to porcine reproductive and respiratory syndrome, which was mentioned by the noble Lord, Lord Trees—
I have been looking very carefully at the literature on gene editing for this debate, to remind myself. Although the Minister praises British research—of course we like to promote British research and British universities, being at one myself—I have to say that what I see is that the papers describing the risks of gene editing in detail largely come from other countries, including Asia and America. I do not think we can ignore the fact that there is a wide body of opinion that recognises that this is still a relatively dodgy technique, particularly so in animals, and therefore we need to go carefully before we start to implement it as a sort of service that we might be able to sell.
I am grateful to the noble Lord and will cover that point in a moment.
I was making a point about PRRS, but there are also developments abroad in producing cattle that are more heat tolerant and resistant to climate change. As was pointed out at Second Reading, there is potential to reduce methane emissions from cattle, which is vital for more sustainable agricultural systems.
I agree with the noble Lord, Lord Trees, that there are many examples that demonstrate the potential to bring significant health and welfare benefits to our animal populations and economic benefits to our farming industries. That is why we are looking at this down one end of the telescope. I hope I can persuade noble Lords that this a way that offers great potential, particularly in the area of animal welfare.
It is vital that we create an enabling regulatory environment to translate this research into practical, tangible benefits. This is a key objective of the Bill, and removing animals from the Bill would hinder us from realising any benefits of these technologies for animals. Ensuring that these technologies are used responsibly and enhance animal health and welfare is vital; I think we are all agreed on that. That is why we intend to take a stepwise approach in implementing the Bill, with regulatory changes to the regime for plants first, followed by that for animals. We want to make sure that the framework for animal welfare set out in the Bill is effective, and we will not bring the measures on precision breeding into effect for animals until this system is in place.
It is important we get this right, and that is why we have commissioned Scotland’s Rural College to carry out research to help us develop the application process for animal marketing authorisations. This will focus on the welfare assessment that notifiers will have to carry out to support their welfare declaration. This research will help us determine an appropriate welfare assessment for precision-bred animals and identify the evidence and information that must be submitted to the welfare advisory body along with the notifier’s welfare declaration. The research will involve experts from the Animal Welfare Committee and a wide range of organisations with expertise in animal welfare, genetics and industry practice.
As the noble Lord, Lord Trees has noted, the Bill introduces additional animal welfare standards, over and above existing animal welfare legislation. We are clear that these additional safeguards will complement our existing animal welfare regulatory framework for protecting animals. This includes the Animal Welfare Act 2006, the Welfare of Farmed Animals (England) Regulations 2007 and the Animals (Scientific Procedures) Act 1986. A suite of legislation exists. I absolutely refute the points that have been rightly raised that this can be seen as a fast passage towards higher density occupation of buildings because birds are somehow resistant to diseases caused by tight accommodation. There is already legislation that controls the densities and other animal welfare provisions. The idea that this is somehow going to allow producers to get round existing legislation is not the case, and there are additional animal welfare safeguards within the legislation.
If we want to drive investment in new research and realise the potential benefits for animals, we need to include them in the Bill. By doing so, we are providing a clear signal that the UK is the best place to conduct research and bring products to market.
I move now to the topic of limiting the scope of the Bill to certain animals. As we have already discussed, we know that there are benefits from enabling precision breeding. This technology has the potential to improve the health and welfare of animals. This applies to a range of animal species. I hope that the points I am coming to now will address the points made in the amendments and the remarks of the noble Lord, Lord Winston, the noble Baroness, Lady Bennett, and others.
The definition of animals in this Bill is broad so that the legislation remains durable for future years and to encourage beneficial research and innovation. Much of current research is on animals used in food production. We want to ensure that the potential benefits, such as improved welfare, can be realised across different species in a responsible way as research advances. This includes species that are kept only in this country as companion animals. Independent scientific advice that precision-bred organisms pose no greater risk than traditionally bred organisms applies to farm and companion animals.
To quote one example, hip dysplasia in certain breeds of dog is a devastating condition; it causes a lot of misery for the dog and its owners, and results in the dog’s early death. I do not say that there is some quick and easy path to resolving this, but there is a lot of research going on to traditionally breed out that condition. I want to see this sort of work speeded up. It seems right to include the ability to tackle these sorts of conditions in companion animals in this legislation, with adequate safeguards.
It is important to note that this is just the beginning. We intend to take a step-by-step approach with animals. We will not bring the measures set out in this Bill into effect in relation to any animal until the system to safeguard animal welfare is fully developed and operational. This system is intended to ensure that, before a vertebrate animal or its qualifying progeny can be marketed, their health and welfare will not be adversely affected by any trait that results from precision breeding. As I said, we have started by commissioning Scotland’s Rural College to conduct research that will help develop this application process.
I acknowledge the amendments tabled by noble Lords in relation to the range of animals covered in the Bill. The suggestion from the noble Lord, Lord Krebs, to pursue and build up the step-by-step approach is the right way forward. I hope that noble Lords will be reassured to know that the Bill, as currently drafted, already allows us to take this step-by-step approach through commencement regulations; for instance, by commencing the relevant provisions of the Bill in relation to some animal species before dealing with others. I hope this offers some reassurance to the noble Lord, Lord Winston. I hope that the points I have made will enable noble Lords to not press their amendments.
All I can do is assure noble Lords that nothing will happen before we are in the right position to do it. That is why we have commissioned the work with Scotland’s Rural College, and we are working with important stakeholders such as veterinary colleges and others to make sure that we get this right.
The priority will be to try to do this for farmed animals first, and we want to make sure that we are operating a step-by-step approach. If we put it in the Bill, it may be too prescriptive, because we are in a fast-moving area of science, and it may constrain the ability of the scientific community to progress this if we do it in the wrong way. We want to give as much freedom as possible, and that is why we are adopting this process.
I hope the Minister will forgive me—I have been a complete pest to him this afternoon and will probably continue to be one—but it is nothing to do with the scientific community. That community can take as long as it wants to get the right answers; it is the marketing of these animals that concerns us. We have no problem with the science, providing it is done humanely, and we recognise that that is the Government’s intention because we already have very good legislation to do that, but we have to accept that the science is still uncertain. That is why we are concerned that we might make mistakes.
That is precisely why we want to have the proper regulatory framework in place, and that requires consultation. We also have a flowchart, available on the Bill webpage, that sets out very clearly the process for applying for an animal marketing authorisation. I will not delay noble Lords by going through each of the six steps in the process, but it is very extensive and exhaustive and clearly sets out how we propose to do this.
It gives the kind of reassurance that a lot of noble Lords talked about regarding the public’s acceptance. To address that point, it is a matter of how you put the question: if you do so in the way in which the noble Lord, Lord Trees, just did, mentioning the benefits of the legislation, I think a huge majority of people will support it. If you ask it in a different way, you will get a different answer—that was the problem 25 to 30 years ago.
The noble Lord is right, of course: the scientific community will move at the pace that the money allows it to, and the market will create demand for the research. But we want to make sure that we have a good, proper regulatory process that reassures the public and is clear to developers of these products, so that they can see how they will be required to sit within that sort of framework.
I thank the Minister for his answer and thank everyone who contributed to what has been a very rich, full and very informed debate. I am going to deal first with the structural questions just raised by the noble Baronesses, Lady Hayman of Ullock and Lady Jones of Whitchurch.
We again have this problem that we have to wait for the regulations and trust the Government. I appreciate that the Minister was doing his best to persuade us, and I felt that he really wanted the opportunity to have a PowerPoint presentation here to show us a slide of his flowchart. But this is all about taking it on trust. Almost certainly, in the timeframe the Minister referred to, we are talking of not the same Government implementing this—I am not casting any aspersions on who the next Government might be—and the noble Lord not being in a position to guarantee what will happen in the future. We are left with this uncertainty and it not being clear. We know that tomorrow will test your Lordships’ House on just how much it is prepared to stand up against regulations. We shall see what happens then.
The Minister responded to me on the standards of what I call factory farming. He said that there is already legislation on this, but I say that that legislation is grossly inadequate and that we have huge disease problems because of that. Tightening up animal welfare regulations and regulations for housing animals in this country would greatly reduce the need to deal with problems of disease.
It is interesting that the Minister also said, perhaps a couple of times, that including animals is about making the UK the best place to conduct research. I come back to the point I made on an earlier group about whether this Bill is for animal welfare, food security for farmers, or for our biotechnology industry. It appears that we are hearing that it is for the biotechnology industry.
I am not going to run through all the contributions, because the noble Baronesses, Lady Parminter and Lady Hayman, have already provided us with a good summary, but I will draw together the responses from the Minister and a number of others, including the noble Lords, Lord Trees and Lord Cameron of Dillington. There have been suggestions about tackling disease, but we are talking about ecological niches here. Let us say you produce pigs that are entirely resistant to a particular disease; you are producing resistance to one species or one threat. You are very unlikely to produce widespread resistance, so you are opening up an ecological niche for another disease to come in, if you keep animals in conditions that allow that to happen.
We can take a practical example from what is happening in human society at this moment. Over many centuries, human societies have had conditions that have allowed the spread of a wide range of respiratory diseases.
I apologise to the noble Lord if I am sending him to sleep, but this is a complex area. Patent lawyers will dance on the head of a pin on some of these issues. As I said, we have worked with the Intellectual Property Office to get this exactly right and to address precisely the point he made earlier about some of the difficulties that were faced, with large international companies owning the rights to seed entitlements. That caused great difficulty in the past.
I shall just read one bit to him again, and if the noble Lord could try to stay awake, it will be an achievement that I will rejoice in. The Bill does not make any changes to laws associated with obtaining a patent; nor does it alter the process by which an applicant would apply for patent protections. Breeders wishing to patent their precision-bred plant or animal should therefore undertake this process in the same manner as for all other inventions and under the guidance of the Intellectual Property Office.
The Bill is also an attempt to provide precisely the balance that the noble Baroness, Lady Wilcox, stressed. We want to secure the rights of those who are investing enormous amounts of money in the development of these technologies, while also not making it impossible for farmers—precisely the people we want to have access to these technologies—to have access. That is the balance we are seeking to achieve.
I can work only on the best legal advice I am given. There are noble Lords in this Committee whose speciality is intellectual property law, and I am sure they could dance much more dextrously on the head of that particular pin than I.
I wonder if we could “strictly” stop dancing just for a moment and come back to the question of the noble Lord, Lord Krebs. I have to declare an interest in the register: I have a company called Atazoa, which is responsible for modifying the genes not of embryos but of individual sperm. We have of course also been working with eggs. This is before fertilisation—before the organism is formed. That is subject to a number of patents which have raised a certain amount of money for our research, and the research has been moderately fruitful—not as fruitful as I would have liked it to have been; it has not made any major changes.
There is an issue here. First, what happens if we produce a farm animal as a result of that technique? Does that come under the licence or not? Secondly, during the process of gene editing, it is very probable that people will make new editions to the modification of techniques to find new ways to put together what is quite a complex process; even though it is fairly efficient and simple to do, it remains complex. What happens, for example, with regards to improvement of the technology, rather than the animal husbandry side of it? Does the patent there still stand or not?
I have to be honest with the noble Lord and say that I will write to him on this. He makes a very good point. I can think of it only in terms of a standard invention. In intellectual property terms, you secure the creation of whatever it is, with whatever characteristic it has, and others may come along and improve it. The line on intellectual property exists until they change it beyond its original purpose, and I quoted the other criteria earlier. I am going to write to both the noble Lord, Lord Krebs, and the noble Lord, Lord Winston, to give more precise answers to those particular points. With that, I hope the noble Baroness is willing to withdraw her amendment.
I would love to hear from the Minister say “finally” again in just a second. One of the issues I would like him briefly to address—probably in a note, not now—would be how to classify a plant organism, for example, which has been treated not only by gene editing but also by, say, radiation. I mention this is because a recent publication by Amritha and Shah in the last few months shows that, by combining those techniques, the resulting edit is even more successful. It seems that is hardly a natural process, but I do not know whether that is something to discuss now.
The other issue is that we are all obviously agreed about climate change, but what I think concerns a lot of people who are arguing on my side of the Chamber is that modifying plants could make us, the plants or the land more vulnerable to climate change. That is something we need to be thinking about during the course of the Bill.
I take the noble Lord’s points. We have to make it clear that we will not allow organisms to come on to the market that would somehow make it harder for us to adapt. There are so many benefits that we can introduce to tackle things such as drought and other issues that plague farmers. We have climate change affecting farmers here and now in this country. It is not something that is happening in Pacific countries alone; it is in our country, and we need to give farmers the tools to deal with it.
On the noble Lord’s other point, as the noble Lord, Lord Krebs, said earlier, irradiation—if I have got the word right—is an established part of plant breeding today. He is right. I can see an overlap in this, but I will write to him and make sure that we give him the facts that he needs. With that, I hope that we can progress.
That was a very complicated statement. I think the noble Lord, Lord Krebs, had a bit of difficulty with it, and so did I, so I shall read it with great interest in Hansard. Perhaps we can discuss one or two issues that the Minister raised. I think he said, though maybe I misheard, that there have been no recorded changes in the genome or in the DNA of animals that have been modified using the CRISPR technology, for example. I should like to get back to the noble Lord in order to share with him my understanding and to present him with some reports from the literature which argues that this actually has happened and that the introduction of stray DNA, as well as off-target mutation, is a real issue. But now is not the time to discuss this. We shall probably have to leave it until Report.
I am sure that we are basically working towards the same thing. However, it seems to me that, if you own a picture—a Rembrandt, for example—you do not automatically sell it as a Rembrandt; you sell it for what you think it is worth, or what its provenance is. So the provenance of what we sell in terms of our animals to other people is just as important. It is part of a proper sale. If in fact it depends on the genome and the nature of the genes—whether they are expressing or not expressing, and whether the progeny is normal—that, I would argue, is important to the person who is going to buy it. It is essential that we try to be honest, open and transparent.
That is absolutely right. I would just say to the noble Lord that ACRE assessed the evidence put to it by the scientific community. I repeat what I said. Many recent gene-editing studies on animals have reported no incidences of unintended genomic changes when using CRISPR-Cas9. If the noble Lord has information that ACRE should be considering in relation to this, I would be very happy to connect him with ACRE. But that is also the same scientific opinion that was reached by the European Food Safety Authority, which advises the EU Commission. But the noble Lord is absolutely right that the science on this is moving. There are advances being made, not just here but internationally as well, and we must have the best possible advice to allow Ministers to take the best possible decisions.
(2 years, 1 month ago)
Lords ChamberI apologise for interrupting at this late stage of the debate, which has been really thoughtful and helpful.
The Minister might want to consider the difference between DNA that is naturally produced and is what the Bill is talking about and DNA that is produced in a gene sequencer, completely chemically. An issue here is that there is not really any difference at all. We must consider that very carefully.
Do not forget, too, in spite of your spelling, that if three base pairs are missing, for example, you end up with cystic fibrosis, which is a killer. One base pair will do with many diseases, so there is a real problem with these definitions. I hope the Minister will forgive me for interrupting; I do not expect an answer, but it is something we will need to consider during the next stage of the Bill.
I am not going to debate with the noble Lord, because he knows much more about this than me, and I know that I would sound even weaker if I just read out a line that has been written. But I value his contribution and I hope to tease out some of these matters as we go through the remaining stages of the Bill.
In response to a point made by the noble Lord, Lord Krebs—I hope I have got this right—in some cases, transgenic organisms will be used as an intermediate step in the development of precision-bred organisms. However, for the end product to be classed as a precision-bred organism, genomic features that could not have occurred naturally or resulted from traditional breeding must be removed from these organisms. For example, this would include removing CRISPR-Cas9 genes from gene-edited organisms.
DNA fragments from sexually incompatible species are naturally present in many organisms. This is in line with what could occur naturally—and I hope the noble Lord, Lord Winston, is on board on this. Therefore, we are allowing for foreign DNA to be present in precision-bred organisms only so long as this DNA does not serve any function and is within the range achievable through natural processes.
The noble Lord, Lord Krebs, also asked why companion animals are in the Bill, and a number of other noble Lords referred to this. Independent scientific experts advise that precision-bred organisms pose no greater risk to the environment or health than traditionally bred organisms. This applies to companion animals, as well as farmed animals. We are aware of precision breeding research that is already taking place on animals that could lead to positive welfare outcomes, such as increased disease resistance. Although there is less research taking place on companion animals, there is early research on the use of precision breeding—for example, in improving hip dysplasia in dogs. We do not want to restrict the potential benefits that can be achieved to improve the health and welfare of these species. That is why they are included in this Bill. I would say that that is not a priority, but it is definitely important that we future-proof the Bill.
We are not aware of the specific project to which my noble friend Lord Jopling referred and I would be interested to hear about it. A project that may be relevant was recently authorised by the Secretary of State for a field trial of GM and gene-edited barley. This is related to the concept about which my noble friend spoke. It is being undertaken by the Cambridge Crop Science Centre and is investigating the potential to increase yields by altering the interaction between the plant’s roots and the soil micro-organisms with which they are associated. We are not aware that any research group has yet succeeded in developing wheat plants in the laboratory that can fix nitrogen like legumes can.
I agree with the noble Lord, Lord Trees, that disease is a welfare issue. I cannot put it better than he did. The Government are committed to maintaining our already high standards in animal welfare, and we want to improve and build on that record. I assure noble Lords that this Bill will not lower the standards set by current legislation. He refers to zoonotic diseases and there is a human health element to this. This Government are very much signed up to the “one health” concept, so there is a wider benefit from this.
I will address the questions about why we are including provisions for animals in this Bill. Precision-breeding technologies such as gene editing have the potential to improve the health and welfare of animals, and improve the sustainability and resilience of farming systems. Such technologies can enable new traits to be developed more precisely and more efficiently than traditional breeding. The noble Lord, Lord Winston, made a really interesting point about genetic diversity. I cannot remember what percentage it is, but many of our dairy cows are descended from a very small number of bulls. It could be that in the future, because of recent trends, something occurs that endangers the health of many of them—I am not saying the whole dairy herd—because of their genetic uniformity. We want to be able to correct circumstances such as those as quickly as possible, and this legislation should allow us to de-risk that situation.
Research in farmed animals is already leading to the development of animals that have increased resistance against some devastating diseases. A number of noble Lords have spoken about the great organisations we have in this country: for example, the Roslin Institute and others such as Genus have developed gene-edited pigs with resistance to porcine reproductive and respiratory syndrome, or PRRS. It is a disease that causes mortality and major welfare issues in pig populations globally. This has been referred to by a number of noble Lords.
Whilst there is great potential for increasing innovation, we recognise that there is a need to safeguard animal welfare in the new regulatory framework. That is why, as I have already said, we are taking a step-by-step approach, facilitating use of precision-breeding technologies in relation to plants first followed by animals later. The measures in the Bill are designed to ensure that the health and welfare of relevant animals will not be adversely affected by any trait that results from precision breeding. To provide some further reassurance, I would also like to take this opportunity to expand on what the system for protecting animal welfare will look like. I am mindful of the time, but I will be as brief as I can.
Before marketing a precision-bred vertebrate animal, developers will need to provide assurances to confirm that the health and welfare of the animal will not be adversely affected by any trait resulting from precision breeding. This will be in the form of an animal welfare declaration and accompanying evidence. The Secretary of State will need to be satisfied with the declaration before issuing a precision-bred animal marketing authorisation, after which point a precision-bred animal can be marketed. This process will also involve an independent scientific assessment of the declaration by a welfare advisory body. We have also commissioned a research project to help us design the animal welfare declaration process and will work closely with a wide range of stakeholders as this work progresses.
I hope my words, the ongoing research project and engagement on these issues will provide noble Lords with some assurance that we fully acknowledge the importance of animal welfare, and we will continue to protect the high standards that we are proud to uphold.
I turn to labelling and the issues raised by the noble Lord, Lord Rooker, and others. The Bill will provide the Food Standards Agency with the ability, through regulations to be made by the Secretary of State, to introduce a new proportionate and science-based food and feed authorisation process. This will include a pre-market risk assessment for food and feed products developed using precision-bred organisms. The FSA’s role is not being diminished but enhanced—we could not be doing this without it—and it has produced some really interesting work in support of what we are doing.
I will address the points on traceability made by the noble Lord, Lord Rooker, and others. To ensure transparency, there will also be a public register of authorised precision-bred organisms for food and feed uses. This will provide consumers, industry and enforcement authorities with information on the precision-bred organism authorisation date, product, developer, characteristics, and food or feed uses. This will give clarity on food business operators involved in the supply of precision-bred organism food and feed products and enable traceability back to source.
A number of noble Lords have raised concerns about the delegated powers. Let me assure them that this is not a skeleton Bill. The powers supplement the principal policy measures which are set out on the face of the Bill and are quite specific and technical in how they are intended to be used. Your Lordships will know that delegated powers serve a valuable purpose, and it is always important to assess them in context. Simply counting up the number of powers in a given Bill is not necessarily meaningful. There are Henry VIII powers, which I know that your Lordships are quite rightly keen to scrutinise. They exist in Clause1(8), Clause 10(2) and Clause 42(1). I am sure that we will discuss those if noble Lords give this Bill the boost that it needs to get into Committee. I will hopefully be able to satisfy your Lordships about the need for them and the proportionality with which they have been put in the Bill.
I am coming to the end of my remarks, but I must address the points made by the noble Baroness, Lady Parminter, the noble Earls, Lord Caithness and Lord Devon, and the noble Lord, Lord Carrington, about trade. They quite rightly want to ensure that trade will not be negatively affected by this Bill. The international regulatory regime for precision-bred products is rapidly evolving. Many countries, as has already been said, have already amended their equivalent regulations, including the United States, Canada, Japan, and Argentina. Our proposed approach would help facilitate greater trade with those countries that have already adopted a similar approach to the regulation of precision-bred organisms.
With regard to the EU, this summer it conducted a consultation on legislation for plants produced by certain new genomic techniques, which is the term it uses for techniques such as gene editing. Some 80% of the respondents agreed that the existing GMO legislation was not adequate for plants, and more than 65% mentioned negative consequences if the regulations were not amended. These consequences included the loss of tools to tackle climate change, to develop more resilient crop varieties and to reduce the use of phytosanitary products. In response to the point made by my noble friend Lord Lansley, we will continue to monitor the position of the EU on precision-bred products and on UK/EU trade implications for products developed using precision breeding.
As things stand, the noble Baroness, Lady Parminter, is absolutely right. If we pass this Bill, some material produced through precision breeding and sold into Europe would be treated as a GMO there, but they are moving fast and we want to make sure that we are too. The global market value for gene editing is estimated at £2.7 billion in 2020 and expected to rise to more than £7 billion by 2026. I therefore ask noble Lords to consider the impacts and missed opportunity that would be caused by not supporting this important transition and the scientific basis for it.
Concerns have been raised about the impact assessment. I reassure noble Lords that this red rating is not a reflection on the quality or the ambition of the Bill. The Government are committed to proportionate, science-based regulations and have carefully considered all views and evidence in establishing our approach. The main criticism of the RPC is that the description of the policy differed between the initial review notice and the final submission. It felt that the impact assessment had not adequately accounted for the potential impacts arising from this policy change.
We are clear that at no point has the policy changed. The final submission had small changes in terminology such as changing the title of the Bill from “gene editing” to “precision breeding”. In our engagement and evidence-gathering, researchers and developers were made aware of the policy intention, and that the name had not been finalised, and so our expectation is that the change of the name to precision breeding will be of no impact on researchers or developers.
In response to the RPC’s comments, work is under way to gather further evidence from stakeholders and additional consumer insight data to provide more detail on the impacts to businesses and to bolster the cost-benefit analysis. We are also seeking to provide information to give more clarity on the policy intention, the Bill’s objectives and the options appraisal. Defra is working closely with the RPC and will submit an enactment impact assessment which will address its comments, and this will reflect any amendments made to the Bill as it progresses through Parliament.
On the point made by the noble Baroness, Lady Jones, about pausing the Bill, the policy has not changed. His Majesty’s Government are absolutely committed to supporting proportionate, science-based regulation. Our engagement and evidence-gathering will, I hope, address her concerns.
We recognise that the devolved Administrations’ positions regarding this legislation differ. My department has had very good conversations with a number of people. I have meetings next week with the devolved Administration in Wales and we will be talking to the Scottish Government as well. The noble Earl, Lord Stair, raised the point that this is a devolved issue. The Scottish Government have declined to join the Bill but the Welsh Government remain open to discussions via the common frameworks. We also engage with leading research organisations: with the Roslin Institute and the James Hutton Institute in Scotland, and with Aberystwyth University and Bangor University in Wales. These are world-leading organisations and they are calling for this kind of legislation. The electoral dynamic will, of course, differ in different parts of these islands and we want to make sure that we are talking to and working with the devolved Governments, and that we come to the right conclusions. I hope that we can persuade them to come along with us.
The noble Earl, Lord Devon, talked about the IP implications and whether precision-bred crops and organisms can be patented. The patent system exists to encourage inventions by offering time-limited exclusive rights in exchange for making the invention public, allowing others to further develop it. I am preaching to the choir; he is, of course, an expert on this. Patent rights are available in the UK in the area of gene editing, including plants and animals modified by such techniques. A number of patent applications have been filed and patents granted that relate to the genome-editing tool CRISPR.
The noble Earl and others also raised issues relating to the World Trade Organization. In 2018, a joint statement issued to the World Trade Organization signed by 13 countries stated that Governments should
“avoid arbitrary and unjustifiable distinctions”
between those crops developed through precision breeding and those developed through conventional breeding. The signatories included Canada, Argentina, Australia, Brazil and the USA. We are moving in that direction.
I have not had time to answer everyone’s points, even though I have been rather lengthy in my reply. It is important that we have open conversations. This has been an incredibly fascinating debate. I am encouraged by the level of support for the Bill. I hope we can progress it through the House. I beg to move.
(2 years, 1 month ago)
Lords ChamberMy Lords, this is absolutely vital, as was brought home to me yesterday at the reception organised by TIAH and the noble Lord, Lord Curry. Teaching people the necessary skills is vital if we are to see the average age of farmers—which is my age, 62—come right down, and we can achieve that only if they have them.
My Lords, the Government say they want to protect families. Is the noble Lord fully aware of the epigenetic effects of a poor diet on literally thousands of children in hunger poverty? The Dutch winter disease, for example, showed very clearly that the long-term effects on cognitive ability and general health go right through to middle and old age. Can we be absolutely certain that the Government will do all they can to secure food, rather than worrying about some of the other aspects of the environment?
The noble Lord is absolutely right. There is ever-increasing evidence that poor diet makes individuals, particularly young people, susceptible to diseases not just while they are young but right through their lives. That is why our food strategy is not just a Defra strategy but must be across government; it relies on the expertise of people such as the noble Lord.